Goldman Sachs Adds Alexion Pharmaceuticals (ALXN) to Conviction Buy List

Goldman Sachs add Alexion Pharmaceuticals (NASDAQ: ALXN) to its Conviction Buy List with a price target of $91 (up from $83), suggesting 17% Upside

The firm is calling ALXN "one of the most attractive stories in biotech."

Goldman's analyst highlights: (1) sustainable high growth potential when growth is hard to find, and a 30%+ top-line and bottom-line CAGR in 2011-2015E; (2) a diversifying ultra-rare drug franchise (Enobia brings in another late-stage growth driver), which we see as most shielded from political and pricing risks which the industry faces; and (3) an attractive M&A candidate; ALXN's key asset Soliris is wholly owned and has a long terminal value.

For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.

Shares of Alexion Pharmaceuticals closed at $77.78 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Freedom Broker Upgrades Walmart (WMT) to Buy
• Nomura/Instinet Upgrades Sunway Healthcare Holdings (SUNMED:MK) to Buy
• Morgan Stanley Upgrades Merck (MRK) to Overweight